Profile data is unavailable for this security.
About the company
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
- Revenue in USD (TTM)142.77m
- Net income in USD-80.04m
- Incorporated2016
- Employees162.00
- LocationARS Pharmaceuticals Inc11682 El Camino Real, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 771-9307
- Fax+1 (302) 636-5454
- Websitehttps://ars-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MapLight Therapeutics Inc | 0.00 | -92.43m | 781.32m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Janux Therapeutics Inc | 10.00m | -101.90m | 789.74m | 74.00 | -- | 0.8084 | -- | 78.97 | -1.67 | -1.67 | 0.1649 | 16.24 | 0.0116 | -- | -- | 135,135.10 | -11.85 | -13.75 | -12.17 | -14.23 | -- | -- | -1,018.95 | -743.21 | -- | -- | 0.00 | -- | 30.99 | -- | -18.36 | -- | -- | -- |
| Omeros Corp | 0.00 | -121.24m | 811.10m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| Xencor Inc | 167.36m | -138.75m | 829.79m | 250.00 | -- | 1.33 | -- | 4.96 | -1.88 | -1.88 | 2.26 | 8.76 | 0.1807 | -- | 10.46 | 669,428.00 | -15.07 | -9.89 | -16.65 | -10.95 | -- | -- | -83.42 | -48.58 | -- | -12.12 | 0.1755 | -- | -36.72 | -6.75 | -74.73 | -- | -2.93 | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 832.44m | 62.00 | -- | 2.58 | -- | 140.69 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 870.86m | 162.00 | -- | 5.90 | -- | 6.10 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Evommune Inc | 3.00m | -66.26m | 878.89m | 45.00 | -- | -- | -- | 292.96 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| AbCellera Biologics Inc | 35.32m | -171.68m | 880.05m | 596.00 | -- | 0.9119 | -- | 24.91 | -0.5765 | -0.5765 | 0.1187 | 3.22 | 0.0257 | -- | 0.97 | 59,268.46 | -12.49 | 2.01 | -13.20 | 2.20 | -- | -- | -486.01 | 10.48 | -- | -- | 0.00 | 0.00 | -24.17 | 19.95 | -11.24 | -- | 81.35 | -- |
| Aktis Oncology Inc | 5.56m | -60.65m | 906.63m | -- | -- | -- | -- | 163.06 | -1.20 | -1.20 | 0.1098 | 3.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,090.81 | -- | -- | -- | 0.00 | -- | -- | -- | -53.56 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 913.47m | -- | 57.21 | 1.42 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 920.03m | 119.00 | 13.49 | 8.35 | 31.40 | 8.10 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 925.53m | 52.00 | -- | 3.00 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| GH Research PLC | 0.00 | -42.92m | 931.06m | 50.00 | -- | 3.20 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| Fortrea Holdings Inc | 2.76bn | -1.03bn | 948.95m | 14.50k | -- | 1.63 | -- | 0.3438 | -11.38 | -11.24 | 30.33 | 6.30 | 0.8617 | -- | 4.08 | 178,058.10 | -32.08 | -- | -43.77 | -- | 18.61 | -- | -37.23 | -- | -- | -0.5534 | 0.6598 | -- | -5.14 | -- | -756.47 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to ARS Pharmaceuticals Inc's reporting currency: US Dollar USD
38.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 10.86m | 10.99% |
| Rubric Capital Management LPas of 30 Sep 2025 | 4.50m | 4.55% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.35m | 4.40% |
| abrdn, Inc.as of 31 Dec 2025 | 3.56m | 3.60% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.01m | 3.05% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.90m | 2.93% |
| AllianceBernstein LPas of 30 Sep 2025 | 2.64m | 2.67% |
| Franklin Advisers, Inc.as of 30 Sep 2025 | 2.40m | 2.43% |
| UBS Securities LLCas of 31 Dec 2025 | 1.96m | 1.98% |
| Casdin Capital LLCas of 30 Sep 2025 | 1.60m | 1.62% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
